CurrentBlue Cross Blue Shield - IowaPolicy N/A

Cryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

Defines coverage stance for cryoablation, radiofrequency ablation, and laser ablation of the posterior nasal nerve for adults with chronic (allergic or nonallergic) rhinitis, focusing on patients refractory to medical management; applies to Wellmark/Blue Cross Blue Shield - Iowa determinations.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyCryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

Policy CodePolicy N/A

Change TypeAnnual review — renewed

Effective DateOriginal Effective Date:

Next Review DateApril 2025

Key ActionDocument prior medical management and inadequate response (e.g., intranasal steroid trial or ≥3 months medical therapy) when requesting consideration.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

ClariFix, RhinAerDevices discussed

1 RCTRCTs

SeveralNonrandomized studies

≤3 monthsShort RCT follow-up

No FDA clearance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Renewed Apr 2025Policy action

Coverage Criteria and Evidence Summary

inv-01: Not established / Investigational — Coverage stance and rationale

Policy coverage stance and rationale:

Investigational procedures: Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis (allergic or nonallergic) are considered investigational

Policy conclusion based on insufficient evidence to determine improvement in net health outcome; RCTs with clearly defined refractory populations and adequate comparators are lacking or limited

inv-02: Coverage criteria (evidence-informed) — Covered when ALL of the following are met

Covered when ALL of the following are met (evidence-based criteria summarized from study inclusion criteria and populations):

Population: Adult patients (≥18 years) with chronic allergic or nonallergic rhinitisduration >3 months or as documented

Chronic rhinitis defined as rhinorrhea with or without congestion despite medical therapy lasting >3 months.

Prior medical management: Documented inadequate response to medical therapy (examples used in studies: minimum 4 weeks of intranasal steroid or failure of medical therapy for at least 3 months)as documented in medical record

Definitions of refractory varied across studies; documentation of prior therapies and outcomes required.

Anatomic suitability: No anatomic limitations that prevent visualization/access to posterior nasal cavity (e.g., severe septal deviation, polyps, recent posterior nasal surgery) per study exclusionsclinician assessment

Trials excluded patients with structural barriers that preclude device placement.

inv-03: Coverage evidence considerations — evidence-based coverage considerations for ablative procedures

Evidence-based coverage considerations for ablative procedures:

RCT evidence exists but applicability limited: Randomized sham-controlled trials for cryoablation (ClariFix) and radiofrequency ablation (RhinAer) showed statistically significant symptom improvement versus sham, but trials did not consistently document enrollment of patients refractory to medical management, limiting applicability to intended-use population.

See RCT descriptions and limitations in the evidence summaries.

Nonrandomized evidence limitations: Multiple single-arm prospective studies reported symptom improvement for cryoablation, radiofrequency, and laser ablation, but lacked comparators, were open-label, had variable definitions of refractory disease, and had notable loss to follow-up—reducing strength of evidence.

These limitations reduce confidence in net health benefit estimates.

Requirement for demonstrating medical management failure: Because trial enrollment and refractory definitions were inconsistent (examples: ≥4 weeks intranasal steroid or ≥3 months of medical therapy), documentation that conservative medical therapy was tried and failed should inform coverage decisions.

inv-04: Coverage-relevant evidence and guideline synthesis — Evidence and guideline context for posterior nasal nerve ablation

Evidence and guideline context for posterior nasal nerve ablation:

Evidence for radiofrequency ablation: One randomized sham-controlled trial of radiofrequency ablation (RhinAer) demonstrated statistical improvement versus sham; several nonrandomized studies also report symptom improvement, but limitations include unclear enrollment regarding medical refractoriness and limited long-term data.

Supports cautious consideration when patient selection mirrors trial populations.

Evidence for laser ablation consists of a single nonrandomized study reporting symptom improvement but lacking a comparator and clear refractory definitions; comparative evidence is insufficient.

Insufficient evidence to establish net health benefit.

Guideline positions: Professional society statements provide conditional support: AAAAI (2023) grades evidence as C and lists posterior nasal nerve ablation as an option for patients who failed medical management; AAO (2023) and the American Rhinologic Society endorse or support use in medically refractory cases and do not consider it experimental.

Guidelines emphasize limited long-term data and recommend use in properly selected, medically refractory patients.

There are no FDA-cleared laser ablation devices for the treatment of chronic rhinitis; laser ablation for chronic rhinitis is explicitly listed as investigational in this policy. The policy concludes the evidence is insufficient to determine improvement in net health outcome for laser ablation, and therefore procedures using laser devices for chronic rhinitis are considered investigational and may be subject to denial.

Clinical trial exclusion criteria and study protocols list anatomic factors that can prevent safe or effective treatment. Examples include clinically significant nasal or sinus anatomy that limits visualization or access to the posterior nasal cavity (for example severe septal deviation, large polyps, or other structural barriers) or prior surgery that alters posterior nasal cavity anatomy; such anatomic limitations were reasons for exclusion from multiple nonrandomized studies and should be considered when assessing procedural suitability.

The evidence for laser ablation is limited to a single nonrandomized, single-arm study (N=32) with only 3 months of follow-up; the study did not define criteria for being resistant to medical management. Because of the small sample size, lack of a comparator group, short follow-up duration, and unclear refractory definitions, the strength and applicability of the laser ablation evidence are limited.

When the only available data are from single-arm or nonrandomized studies without a concurrent comparator and without clearly defined refractory-to-medical-therapy status, the ability to infer benefit is substantially limited. Procedures supported solely by such single-arm evidence are therefore considered investigational in this policy context.

Key randomized and nonrandomized trials frequently did not require or document a prior failed trial of adequate medical therapy as an enrollment criterion. In the absence of documentation that a patient has had an inadequate response to appropriate medical management, procedural intervention lacks the demonstrated intended-use population and may not meet medical necessity requirements.

Procedural ablation (cryo, radiofrequency, or laser) should be considered not medically necessary when the medical record does not document failure of adequate medical management (examples in studies included at least a 4‑week trial of intranasal steroid or ≥3 months of medical therapy). The policy emphasizes that many trials did not clearly enroll refractory patients; without documentation of prior adequate therapy failure, the procedure is not supported by the available evidence.

Available trials and study reports do not reliably establish benefit of radiofrequency or laser ablation in patients who are not clearly refractory to medical management. Because enrollment criteria and definitions of refractory status varied or were unclear, use of these procedures in non‑refractory patients is not supported by the current evidence base.

Procedure and Billing Codes

Codes table referencedmixed

No codes listed

Procedure CPT CodesCPT

31242	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve.
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve.
30999	Unlisted procedure, nose.
31299	Unlisted procedure, accessory sinuses.

Outcome timing — At least 6 months or longer for symptom and quality-of-life outcome assessment

Outcome timingSymptoms and quality-of-life outcomes assessed at least 6 months or longer (per Table 1 outcome timing).

rTNSS timingReflective Total Nasal Symptom Score (rTNSS) assessments: recommend ≥6 months follow-up for primary symptom outcomes.

Quality-of-life timingMiniRQLQ and other QoL measures: assess at ≥6 months to evaluate sustained benefit.

Provider Requirements, Documentation, and Billing Guidance

Denial Risk

Investigational — documentation risk

Cryoablation, radiofrequency ablation, and laser ablation for chronic rhinitis are considered investigational. Claims may be denied if documentation does not demonstrate that the patient had chronic allergic or nonallergic rhinitis refractory to adequate medical management prior to the procedure.

Investigational procedures may be denied if the medical record lacks documentation of prior medical therapy and failure.

Documentation Required

Required and suggested supporting clinical documentation

Document that the patient is an adult (≥18 years) with a diagnosis of chronic allergic or nonallergic rhinitis and that symptoms have persisted despite a trial of appropriate medical therapy. Include duration of symptoms, prior medications tried, dates of treatment, and response or lack of response to each therapy.

Required: age, diagnosis, symptom duration (e.g., ≥3 months), and statement that condition is refractory to medical management.

Clinical Background

Background: Chronic rhinitis — which includes allergic and nonallergic forms — causes persistent rhinorrhea and/or nasal congestion and can substantially impair quality of life. First‑line management is medical therapy (intranasal steroids, anticholinergics, decongestants, antihistamines). Approximately 10%–22% of patients remain symptomatic despite medical therapy and may be considered for procedural options, but any procedural approach should be considered only after documented failure of adequate medical management and assessment of anatomic suitability.

Definitions and Device/Procedure Descriptions

Chronic rhinitis definition

DefinitionRhinorrhea with or without nasal congestion persisting despite medical therapy for longer than 3 months.

ContextApplies to adults with chronic allergic or nonallergic rhinitis considered for procedural interventions.

Procedure descriptions — cryoablation, radiofrequency ablation, laser ablation device summaries

CryoablationUses nitrous oxide to freeze posterior nasal nerve tissue (ClariFix); performed under local anesthesia to ablate nerve branches and reduce secretions/vascular hyperreactivity.

Radiofrequency ablationHandheld RhinAer stylus delivers radiofrequency energy (~60°C) to posterior nasal nerve region under local anesthesia to reduce parasympathetic-driven nasal secretions.

Laser ablation

Policy Revision History

April 2025policy_renewalLatest

Policy renewed following annual review; most recent administrative action recorded.

April 2024annual_review

Policy underwent annual review; administrative actions recorded in policy history.

April 2023clinical_review

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyCryoablation, Radiofrequency Ablation and Laser Ablation for Treatment of Chronic Rhinitis

Policy CodePolicy N/A

Change TypeAnnual review — renewed

Effective DateOriginal Effective Date:

Next Review DateApril 2025

Key ActionDocument prior medical management and inadequate response (e.g., intranasal steroid trial or ≥3 months medical therapy) when requesting consideration.

SourceLink

On This Page

as documented (e.g., medication trials and duration)

Absence of clear refractory documentation may preclude applicability of trial results.

Suggested: medication names, doses, start/stop dates, objective symptom scores (if available), and prior procedural history.

Step Therapy

Expect medication trials before procedures

Prior medical management should be attempted and documented before considering ablation procedures. Professional guidelines and the reviewed studies commonly required failure of medical therapy; absence of such documentation is a frequent reason studies could not be generalized to the refractory population.

Document trials of pharmacotherapy such as intranasal corticosteroids, intranasal anticholinergic (e.g., ipratropium), antihistamines, and decongestants as appropriate.
If available, include validated symptom scores (e.g., rTNSS/TNSS) before and after medical therapy.

Step Therapy

Stepwise medical therapy expected prior to procedure

Specify prior stepwise medical therapies and duration before the procedure. The literature and consensus statements describe variable definitions of “refractory” (commonly ≥4 weeks of intranasal steroid therapy or ≥3 months of failed medical therapy); therefore, document the sequence and minimum durations of treatments attempted.

At minimum, document failure of a trial of intranasal corticosteroids (often ≥4 weeks) and other appropriate therapies (e.g., intranasal ipratropium, antihistamines).
If device-specific evidence was used to support treatment, show that the patient met similar refractory-to-medical-management criteria as in the studies (e.g., ≥4 weeks intranasal steroid or ≥3 months overall).

Laser energy applied to posterior nasal nerve branches; currently no FDA-cleared laser devices for chronic rhinitis indication.

Chronic rhinitis — definition variant (3 months)

Chronic rhinitis (variant)Rhinorrhea with or without nasal congestion symptoms despite medical therapy lasting longer than 3 months.

Clinical applicationUsed as the chronicity criterion in study inclusion and policy considerations for procedural interventions.

Adult populationDefinition referenced for adults (≥18 years) with allergic or nonallergic rhinitis refractory to medical management.

Allergic rhinitis definition — IgE-mediated description

Allergic rhinitis definitionAn immunoglobulin E (IgE)-mediated inflammatory response of the nasal mucous membranes after exposure to inhaled allergens causing rhinorrhea, congestion, itching, and sneezing.

PatternsCan be seasonal or perennial; symptoms may be intermittent or persistent.

Symptoms listedIncludes anterior/postnasal drip, nasal congestion, nasal itching, and sneezing.

rTNSS — reflective Total Nasal Symptom Score outcome definition

rTNSS descriptionReflective Total Nasal Symptom Score (rTNSS) is the sum of 4 subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each scored 0–3 (maximum 12).

Scoring detailsEach symptom rated 0 = none, 1 = mild, 2 = moderate, 3 = severe; total score range 0–12.

Use in trialsrTNSS commonly used as primary symptom outcome in randomized and nonrandomized studies of posterior nasal nerve ablation.

MiniRQLQ — mini Rhinoconjunctivitis Quality of Life Questionnaire definition

MiniRQLQ descriptionMini Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ) is a patient-reported QoL instrument used to assess changes after treatment for rhinitis.

Outcome reportingStudies report MiniRQLQ mean change from baseline and proportion achieving ≥0.4‑point improvement as measures of clinically meaningful QoL change.

TimingQuality-of-life measured with MiniRQLQ typically assessed at follow-up time points including 3 and ≥6 months in studies; policy recommends ≥6 months for durable assessment.

Chronic rhinitis refractory to medical management — definition placeholder

Medically refractory definitionChronic rhinitis refractory to medical management denotes persistent symptoms despite adequate medical therapy; studies variably defined this as inadequate response after a minimum 4 weeks of intranasal steroid or failure of medical therapy for at least 3 months.

Documentation expectationsPrior medical management documentation may include trials of intranasal steroids, anticholinergics, antihistamines, and topical therapies with duration and response noted.

Study variabilityDefinitions of 'refractory' varied across trials and are a noted limitation when applying trial results to intended-use populations.

Last clinical review completed (documented as last review); clinical content and evidence summaries current as of this review.

Original Effective Datepolicy_effective

Original effective date of the policy as established at inception.

Note

Policy renewal / administrative note

Policy renewal: most recent policy action was renewal in April 2025; verify current policy status when submitting authorization or claims.

Policy history: April 2025 — Policy renewed